Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-
- PDF / 745,835 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 36 Downloads / 160 Views
ORIGINAL ARTICLE
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross‑sectional study G. Beccuti1 · F. Guaraldi2,3 · G. Natta1,4 · V. Cambria1 · N. Prencipe1 · A. Cicolin5 · E. Montanaro6 · L. Lopiano6 · E. Ghigo1 · M. Zibetti6 · S. Grottoli1 Received: 6 June 2020 / Accepted: 24 November 2020 © The Author(s) 2020
Abstract Introduction Impulse control disorders (ICDs) have been described as a side effect of dopamine agonists (DAs) in neurological as well as endocrine conditions. Few studies have evaluated the neuropsychological effect of DAs in hyperprolactinemic patients, and these have reported a relationship between DAs and ICDs. Our objective was to screen for ICD symptoms in individuals with DA-treated endocrine conditions. Materials and methods A cross-sectional analysis was conducted on 132 patients with pituitary disorders treated with DAs (DA exposed), as well as 58 patients with pituitary disorders and no history of DA exposure (non-DA exposed). Participants responded to the full version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease (QUIP). Results Compared with the non-DA-exposed group, a higher prevalence of DA-exposed patients tested positive for symptoms of any ICD or related behavior (52% vs. 31%, p
Data Loading...
